B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

PDE4A

MOLECULAR TARGET

phosphodiesterase 4A

UniProt: P27815NCBI Gene: 514118 compounds

PDE4A (phosphodiesterase 4A) is targeted by 18 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting PDE4A

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Enoximone1.102
2palmidrol [Supplementary Concept]0.691
3Vitamin K 20.691
48-Bromo Cyclic Adenosine Monophosphate0.691
5Anthralin0.691
6Bufexamac0.691
7Cimetidine0.691
8Daptomycin0.691
9Dequalinium0.691
10Disulfiram0.691
11Ertapenem0.691
12Ethynodiol Diacetate0.691
13Hexachlorophene0.691
14Methoxsalen0.691
15Papaverine0.691
16streptonigrin0.691
17Sulfisomidine0.691
18Troglitazone0.691

About PDE4A as a Drug Target

PDE4A (phosphodiesterase 4A) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 18 compounds with documented PDE4A interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

PDE4A inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.